Jupiter Neurosciences, Inc. Common Stock (JUNS) Stock Price

JUNSStock

$2.90−97.62%52W

Market Cap$3.83M

P/E—

PEG Ratio—

Div yield—

Beta0.46

JUNS Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-100.06%

Price vs S&P 500 (4W)2.54%

VGM Score13.60

Book Value / Share (Quarterly)$0.13

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-67.55%

Cash Flow / Share (Quarterly)$-10.91

Price vs S&P 500 (YTD)-108.13%

Net Profit Margin (TTM)-10682.21%

EPS (TTM)$-18.57

10-Day Avg Trading Volume0.12M

EPS Excl Extra (TTM)$-18.57

EPS (Annual)$-18.73

ROI (Annual)-56.50%

Gross Margin (Annual)80.60%

Cash / Share (Quarterly)$2.29

ROA (Last FY)-155.37%

EBITD / Share (TTM)$-19.72

Operating Margin (TTM)-11614.71%

Cash Flow / Share (Annual)$-11.79

P/B Ratio66.71x

P/B Ratio (Quarterly)1067.68x

Net Income / Employee (Annual)$-1,729,000

Net Interest Coverage (TTM)-67.83x

ROA (TTM)-232.79%

EPS Incl Extra (Annual)$-18.73

Current Ratio (Annual)0.65x

Quick Ratio (Quarterly)0.62x

3-Month Avg Trading Volume0.71M

52-Week Price Return-97.62%

Revenue / Employee (TTM)$12,900

Tangible BV / Share (Quarterly)$-0.24

P/S Ratio (Annual)175.70x

Asset Turnover (Annual)0.00x

52-Week High$135.75

EPS Excl Extra (Annual)$-18.73

26-Week Price Return-90.16%

Quick Ratio (Annual)0.63x

13-Week Price Return-77.55%

Total Debt / Equity (Annual)0.04x

Current Ratio (Quarterly)0.66x

Enterprise Value$3.84M

Asset Turnover (TTM)0.01x

Revenue / Employee (Annual)$4,400

Pretax Margin (Annual)-39655.50%

Cash / Share (Annual)$8.25

3-Month Return Std Dev140.43%

Net Income / Employee (TTM)$-1,839,900

ROE (Last FY)-58.48%

Net Interest Coverage (Annual)-19.84x

EPS Basic Excl Extra (Annual)$-18.73

Receivables Turnover (TTM)0.08x

Total Debt / Equity (Quarterly)2.55x

EPS Incl Extra (TTM)$-18.57

Receivables Turnover (Annual)0.03x

ROI (TTM)-329.56%

P/S Ratio (TTM)59.20x

Revenue / Share (Annual)$0.05

Tangible BV / Share (Annual)$-0.23

Forward P/E0.65x

Price vs S&P 500 (52W)-113.16%

Year-to-Date Return-96.20%

5-Day Price Return-4.44%

EPS Normalized (Annual)$-18.73

ROA (5Y Avg)-1228.96%

Net Profit Margin (Annual)-39655.50%

Month-to-Date Return19.06%

EBITD / Share (Annual)$-19.30

Operating Margin (Annual)-40865.69%

LT Debt / Equity (Annual)0.00x

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-18.57

P/B Ratio (Annual)84.90x

Pretax Margin (TTM)-10682.21%

Book Value / Share (Annual)$9.45

Price vs S&P 500 (13W)-80.24%

Beta0.46x

Revenue / Share (TTM)$0.12

ROE (TTM)-352.06%

52-Week Low$2.25

mGradeF

vgmGradeF

JUNS Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q3 2025	Nov 14, 2025	-$6.00	-$5.25	+12.50%(+$0.75)
Q2 2025	Aug 19, 2025	-$5.25	-$5.25	+0.00%(+$0.00)
Q1 2025	May 15, 2025	-$2.25	-$3.75	-66.67%(-$1.50)
Q4 2024	Mar 28, 2025	-$1.50	-$3.75	-150.00%(-$2.25)

JUNS Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.14

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
JUNSJupiter Neurosciences, Inc. Common Stock	—	—	F	59.2x	—	—	—	$2.90
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Jupiter Neurosciences, Inc. Common Stock

Jupiter Neurosciences is a clinical-stage biopharmaceutical company developing a resveratrol-based therapeutic platform to address neuroinflammation in central nervous system diseases. Its lead candidate, JOTROL, targets conditions including Alzheimer's disease, ataxias, and metabolic disorders such as Lysosomal Storage Disorders and mitochondrial diseases.